Should You Sell Teladoc Health Stock As Coronavirus Vaccines Succeed?
As the world stands on the verge of getting vaccines for COVID-19, investors interested in the pandemic theme are faced with a dilemma. Do they sell stocks of companies that have been big winners from the health crisis of 2020, and move on to the Next Big Thing? Or do they hang onto the stocks for the long term?
There is no one answer, of course. But certain companies that had excellent growth prospects before COVID-19 have seen massive growth of their businesses because they were positioned in the sweet spot of trends that the pandemic accelerated. Whereas the growth rates of 2020 will not continue, the thesis for buying their stocks for the long term have been confirmed and even strengthened.
Such a stock is Teladoc Health (NYSE: TDOC). When the pandemic hit in the spring, clinics closed and patients sheltered at home, leaving remote healthcare as a logical option for people with chronic health issues. Teladoc is the leader in the space, with a network of over 50,000 clinicians in 450 sub-specialties available to patients in their homes. The company's revenue soared 63% in the first half of the year.
Source Fool.com
